DUBLIN, Ireland and BRIDGEWATER, N.J., July 18, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that it has initiated an organizational restructuring program to ...

After Amarin's tussle with investor group Sarissa Capital led to a restructuring and a board shuffle, the struggling drugmaker is undergoing its third CEO shake-up in just over a year. This time, the ...

Amarin appointed a new president and CEO Tuesday in the midst of an organizational restructuring aiming to stem its plummeting revenue. Patrick Holt will take over to helm the company, replacing Aaron ...

After Amarin suffered a surprise patent loss for its key drug Vascepa, the company is appealing and generics makers are hoping their arguments hold. Now, one of them has an FDA go-ahead to launch.

Amarin stock has recently seen its consensus analyst price target raised from $11.00 to $12.00. This reflects improved expectations for the company's future performance. This change comes amid growing ...

With sales of its flagship cardiovascular drug flagging, Amarin is implementing a companywide restructuring that considers the reality of the generic competition eating away at its revenue. The ...

Amarin Corporation plc announced a conference call scheduled for July 30, 2025, at 8:00 a.m. ET, to discuss its second quarter 2025 financial results and recent strategic initiatives, featuring ...

Amarin (AMRN 0.27%) is about to make a boatload of money. Probably no one familiar with the biotech would argue that point. In December, the FDA gave the go-ahead to a new label expansion for Amarin's ...

Pharma companies have long demonstrated that they will employ questionable marketing and sales tactics to boost sales, no matter what the impact is on patients’ health. Now Amarin, a small drug maker ...

Plus, how gene-editing company CRISPR Therapeutics just took a big step forward. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. To get started investing, ...

It’s been a wild Monday for Amarin (AMRN). The biopharma company’s stock price is soaring on the readout of a large clinical trial showing its proprietary, prescription formulation of fish oil cut the ...